Abstract:

This white paper presents a data-driven validation of Isogenica’s synthetic VHH antibody libraries, powered by Colibra^® technology, focusing on binding affinity and biophysical stability. Our libraries are mined using high-throughput expression and purification, and consistently generate high-affinity lead panels against human targets such as cell-surface receptors and oncology antigens. Our VHHs demonstrate good biophysical stability, including high solubility, low aggregation, and robust thermal stability, making them highly suitable for drug development. Case study data demonstrates the success of these libraries in identifying diverse, high-affinity binders for two cell-surface targets using strategies like Fc deselection and parallel screening. Compared with traditional discovery methods, Isogenica’s synthetic VHH libraries offer an accelerated, reliable, and scalable process, overcoming immunization biases and enabling the development of novel, patentable sequences for therapeutic applications.

Are you facing time-to-market challenges in drug discovery and seeking novel solutions for your antibody drug development? Isogenica’s Synthetic VHH Libraries offer a faster, more efficient discovery process while maintaining the high-affinity and exceptional biophysical stability required for successful therapeutic development.

The data shared in this white paper validates Isogenica’s synthetic VHH libraries, powered by Colibra^® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy.

What You’ll Learn:

High-Affinity Binding to Diverse Targets

• Lead panels with EC₅₀ values in the low nanomolar range (0.5–30 nM) with no affinity maturation.
• Validated using Octet and SPR for kinetic assessments
• High-affinity antibodies for a wide array of targets, including cell-surface receptors and oncology antigens

Exceptional Biophysical Stability

• VHHs show high solubility, low aggregation, and robust thermal stability
• Rapid high-throughput expression and purification via E. coli
• Monomer content: 70-90% in early stages, most clones >95% after scaling

Recent Case Study

• Identification of high-affinity binders for two cell-surface targets
• Effective Fc deselection and parallel screening to home in on desired epitopes
• Overcomes limitations of traditional antibody discovery

Why it matters:

Compared with traditional discovery methods, Isogenica’s synthetic VHH libraries offer an accelerated, reliable, and scalable process, overcoming immunization biases and enabling the development of novel, patentable sequences for therapeutic applications.